Notice of Results

Advanced Medical Solutions Grp PLC
18 February 2008


For immediate release                                    18 February 2008





                       Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')





                      Notification of Preliminary Results





Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, will announce its preliminary results for the year
ended 31 December 2007 on Tuesday 11 March 2008.



A briefing for analysts will be held at 10.00am on the day of the results at the
offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.









For further information, please contact:


Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director                      Tel: [phone]

www.admedsol.com

Buchanan Communications                             Tel: [phone]

Mark Court / Mary-Jane Johnson

Landsbanki Securities (UK) Ltd                      Tel: [phone]

Shaun Dobson / Claes Spang







Notes to Editors:



Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.



Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the
design, development and manufacture of innovative and technologically advanced
products for woundcare and other medical applications.



In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.



The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing topical wounds sold direct to hospitals or through
distributors.



AMS's technology and products currently serve the majority of the key global
markets and strategic partners.


                      This information is provided by RNS
            The company news service from the London Stock Exchange